Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Viking Therapeutics is now one big step closer to joining Lilly and Novo Nordisk in competing for this huge potential market. Like Lilly's Zepbound, Viking's VK2735 is a combination GLP-1 and GIP ...

Comparing Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) might initially seem odd. The two drugmakers don't seem to have much in common. Eli Lilly is more than 50 times the size of ...

Eli Lilly (NYSE: LLY) has become a giant in what may be a $100 billion market a few years from now. I'm talking about the world of weight loss drugs.